Amiodarone and Photosensitivity: Side Effects & Sun Protection

Amiodarone is a class III antiarrhythmic agent used for life-threatening ventricular arrhythmias and atrial fibrillation. It has one of the most complex and distinctive photosensitivity profiles of any medication — causing both acute phototoxic reactions and a unique, permanent slate-grey or blue-grey skin discoloration (amiodarone-induced dyspigmentation) with prolonged use.

Why Amiodarone Has Such High Photosensitivity Risk

Amiodarone has several pharmacological features that make it an exceptionally potent photosensitizer:

Iodine content. Amiodarone contains two iodine atoms per molecule and constitutes ~37% iodine by weight. Iodine is a chromophore that absorbs UV-A radiation efficiently.

Extreme lipophilicity and tissue accumulation. Amiodarone is highly lipophilic and accumulates in tissues — particularly skin, liver, lung, thyroid, and eyes — where it remains for months to years after discontinuation (half-life 40–55 days). This means photosensitivity can persist long after stopping the drug.

Desethylamiodarone. The major metabolite of amiodarone, which also accumulates in tissues and contributes to photosensitivity.

Two Distinct Photosensitivity Reactions

1. Acute phototoxic reaction (occurs in 25–75% of patients):

• Exaggerated sunburn within hours of UV-A exposure
• Erythema, edema in sun-exposed skin
• May progress to blistering in severe cases
• Reversible — resolves with sun protection

2. Amiodarone-induced dyspigmentation (occurs in 1–10% of long-term users):

• Slate-grey, blue-grey, or violet discoloration of sun-exposed skin (face, hands, forearms)
• Caused by deposition of lipofuscin complexes from amiodarone-induced lysosomal dysfunction in melanocytes
• May take years to develop; develops only in areas with UV exposure (verifying the photosensitivity mechanism)
• Often irreversible — may persist for years after amiodarone discontinuation
• Affects facial appearance significantly; cosmetically distressing

Ocular Effects of Amiodarone

Amiodarone commonly causes corneal microdeposits (amiodarone keratopathy) — whorl-like deposits in the corneal epithelium (vortex keratopathy) visible on slit-lamp examination in 70–100% of patients. These:

• Are dose-related; appear within months of initiation
• Rarely cause significant visual symptoms (usually subclinical)
• Do not cause photophobia directly but can produce halos around lights in some patients
• Resolve slowly after discontinuation

More concerning: optic neuropathy — a rare but serious complication that can cause permanent vision loss.

Prevention and Management

Acute photosensitivity:

• Broad-spectrum SPF 50+ sunscreen daily (UVA-protective: avobenzone, zinc oxide, titanium dioxide)
• Physical protection: long sleeves, wide-brim hats, UV-protective clothing
• Minimize sun exposure — especially in summer months
• Note: sun protection must continue for months after discontinuing amiodarone due to tissue persistence

Dyspigmentation:

• Prevention is the only option — once established, the blue-grey discoloration is largely permanent
• Broad sun protection minimizes the UV trigger for pigmentation
• Laser treatments (Q-switched Nd:YAG) have been used with limited success for dyspigmentation
• Discontinuation of amiodarone allows gradual (but often incomplete) fading over 1–2 years

Cannot simply switch antibiotics — amiodarone is used for serious cardiac arrhythmias that may have no equivalent alternatives. Patients and physicians must weigh cardiac benefit vs. dermatological risk with appropriate sun protection.

Sources

1. Rappersberger K, et al. “Amiodarone-induced skin pigmentation.” J Am Acad Dermatol. 1989;20(2):209-216.
2. Monk BE, Almeyda J. “Amiodarone photosensitivity.” Br Med J. 1989;299(6701):733.
3. Siddoway LA. “Amiodarone: Guidelines for use and monitoring.” Am Fam Physician. 2003;68(11):2189-2196.